Docebo Inc. Research and Development Expense
Docebo Inc. (DCBO) reported Research and Development Expense of $50.12 million for the 12-month period ending 2025-12-31, per its 40-F filed 2026-02-27.
Financial Statements › Expense Statement › Operating Expenses
ifrs-full:ResearchAndDevelopmentExpense · last filed 2026-02-27
- Docebo Inc. research and development expense for the quarter ending 2025-03-31 was $13.40M, a 28.73% increase year-over-year.
- Docebo Inc. research and development expense for the quarter ending 2024-12-31 was $11.58M, a 28.31% increase year-over-year.
- Docebo Inc. research and development expense for the quarter ending 2024-09-30 was $11.15M, a 8.59% increase year-over-year.
- Docebo Inc. research and development expense for the quarter ending 2024-03-31 was $10.41M, a 41.14% increase year-over-year.
| Period end | Research And Development Expense 3 month | Research And Development Expense 6 month | Research And Development Expense 9 month | Research And Development Expense 12 month | Research And Development Expense 12 month as first filed |
|---|---|---|---|---|---|
| 2025-12-31 | $50.12M 40-F · filed 2026-02-27 | ||||
| 2025-03-31 | $13.40M 6-K · filed 2025-05-09 | $24.98M derived: sum of 2 quarters · filed 2026-02-27 | $36.13M derived: sum of 3 quarters · filed 2026-02-27 | ||
| 2024-12-31 | $11.58M derived: 40-F 12 month − 6-K 9 month · filed 2026-02-27 | $22.73M derived: sum of 2 quarters · filed 2026-02-27 | $43.91M 40-F · filed 2026-02-27 | ||
| 2024-09-30 | $11.15M 6-K · filed 2024-11-08 | $32.33M 6-K · filed 2024-11-08 | |||
| 2024-03-31 | $10.41M 6-K · filed 2025-05-09 | $19.43M derived: sum of 2 quarters · filed 2025-05-09 | $29.71M derived: sum of 3 quarters · filed 2025-05-09 | $38.51M derived: sum of 4 quarters · filed 2025-05-09 | |
| 2023-12-31 | $9.02M derived: 40-F 12 month − 6-K 9 month · filed 2025-02-28 | $19.29M derived: sum of 2 quarters · filed 2025-02-28 | $28.10M derived: sum of 3 quarters · filed 2025-02-28 | $35.48M 40-F · filed 2025-02-28 | |
| 2023-09-30 | $10.27M 6-K · filed 2024-11-08 | $19.08M derived: sum of 2 quarters · filed 2024-11-08 | $26.46M 6-K · filed 2024-11-08 | $32.83M derived: sum of 4 quarters · filed 2024-11-08 | |
| 2023-06-30 | $8.81M 6-K · filed 2023-08-10 | $16.18M 6-K · filed 2023-08-10 | $22.56M derived: sum of 3 quarters · filed 2024-05-10 | $28.67M derived: sum of 4 quarters · filed 2024-05-10 | |
| 2023-03-31 | $7.38M 6-K · filed 2024-05-10 | $13.75M derived: sum of 2 quarters · filed 2024-05-10 | $19.86M derived: sum of 3 quarters · filed 2024-05-10 | $25.97M derived: sum of 4 quarters · filed 2024-05-10 | |
| 2022-12-31 | $6.38M derived: 40-F 12 month − 6-K 9 month · filed 2024-02-23 | $12.48M derived: sum of 2 quarters · filed 2024-02-23 | $18.59M derived: sum of 3 quarters · filed 2024-02-23 | $24.78M 40-F · filed 2024-02-23 | |
| 2022-09-30 | $6.11M 6-K · filed 2023-11-09 | $12.21M derived: sum of 2 quarters · filed 2023-11-09 | $18.40M 6-K · filed 2023-11-09 | $23.91M derived: sum of 4 quarters · filed 2023-11-09 | |
| 2022-06-30 | $6.11M 6-K · filed 2023-08-10 | $12.30M 6-K · filed 2023-08-10 | $17.80M derived: sum of 3 quarters · filed 2023-08-10 | $23.28M derived: sum of 4 quarters · filed 2023-08-10 | |
| 2022-03-31 | $6.19M 6-K · filed 2023-05-11 | $11.69M derived: sum of 2 quarters · filed 2023-05-11 | $17.17M derived: sum of 3 quarters · filed 2023-05-11 | $22.41M derived: sum of 4 quarters · filed 2023-05-11 | |
| 2021-12-31 | $5.50M derived: 40-F 12 month − 6-K 9 month · filed 2023-03-09 | $10.99M derived: sum of 2 quarters · filed 2023-03-09 | $16.22M derived: sum of 3 quarters · filed 2023-03-09 | $20.36M 40-F · filed 2023-03-09 | |
| 2021-09-30 | $5.48M 6-K · filed 2022-11-10 | $10.71M derived: sum of 2 quarters · filed 2022-11-10 | $14.86M 6-K · filed 2022-11-10 | ||
| 2021-06-30 | $5.23M 6-K · filed 2022-08-11 | $9.38M 6-K · filed 2022-08-11 | |||
| 2021-03-31 | $4.14M 6-K · filed 2022-05-12 | ||||
| 2020-12-31 | $13.38M 40-F · filed 2022-03-10 | $13.00M 40-F · filed 2021-03-11 | |||
| 2019-12-31 | $9.44M 40-F · filed 2021-03-11 |